| Date | Title | | | 08/24/10 | Raptor Pharmaceutical Provides Financial and Clinical Program Updates| Enrollment in Pivotal Phase 3 Clinical Trial in Cystinosis on Schedule for Completion in Q4 2010 with Results Expected Q1 2011
Phase 2 Clinical Trial in Huntington's Disease to Commence Enrollment in September
NOVATO, Calif., Aug. 24, 2010 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), provides updates on timelines related to its clinical programs including the pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation o... |
|  | | 08/09/10 | Raptor Pharmaceutical Announces Pricing of $15 Million PIPE Financing| NOVATO, Calif., Aug 9, 2010 (GlobeNewswire via COMTEX) --
Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced it has entered into a securities purchase agreement in connection with a private placement, or PIPE financing. Upon the closing of the PIPE financing, Raptor will receive gross proceeds of approximately $15 million resulting from the sale of 4,897,614 units at a purchase price of $3.075 per unit. Each unit consists of one share of Raptor's common stock and ... |
| | | 06/30/10 | Raptor Pharmaceutical Announces License Agreement for Convivia(TM)| Uni Pharma to Market Convivia(TM) in Taiwan
NOVATO, Calif., Jun 30, 2010 (GlobeNewswire via COMTEX) --
Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that it has entered into an exclusive agreement with Uni Pharma Co., Ltd. ("Uni Pharma") to commercialize Convivia(TM), Raptor's proprietary oral formulation of 4-methylpyrazole ("4-MP"), in Taiwan.
Convivia(TM) is designed to reduce systemic acetaldehyde exposure and related symptoms in liver enzyme aldehyd... |
| | | 06/28/10 | Raptor Pharmaceutical Enrolls First Patient in Pivotal Phase 3 Study of DR Cysteamine for the Potential Treatment of Cystinosis| Randomized, Crossover Study to Evaluate DR Cysteamine as a Lower-Dose, More Tolerable Alternative to Immediate-Release Cysteamine
NOVATO, Calif., Jun 28, 2010 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
... |
| | | 06/15/10 | Raptor Pharmaceutical's DR Cysteamine Receives Orphan Medicinal Product Designation From the European Medicines Agency| Potential for 10 Years Market Exclusivity in E.U.
NOVATO, Calif., Jun 15, 2010 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that the European Medicines Agency's ("EMA") Committee for Orphan Medicinal Products ("COMP") has issued a positive opinion recommending orphan medicinal product designation for DR Cysteamine for the potential treatment of cystinosis.
DR Cysteamine is Raptor's proprietary, delayed-release, oral formulation... |
| | | 06/04/10 | Raptor Pharmaceutical to Present at the 9th Annual Needham Healthcare Conference| NOVATO, Calif., Jun 4, 2010 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company focused on delivering new treatment options to underserved patient populations, today announced that Ted Daley, President, will be presenting at the 9th Annual Needham Healthcare Conference in New York City at the Palace Hotel on Thursday, June 10 at 10:40 A.M. ET.
A live webcast and 90-day archive of the presentation will be available at: http://www.raptorpharma.com/... |
| | | 06/02/10 | Raptor Pharmaceutical Licenses Intellectual Property Related to Huntington's Disease From the Weizmann Institute of Science and Niigata University| Phase II Clinical Trial Scheduled to Begin Summer 2010 Lawrence Steinman, M.D. Added to Raptor Advisory Board
NOVATO, Calif., June 2, 2010 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Pr... |
| | | 05/03/10 | Raptor Pharmaceutical Announces Phase 2a NASH Study Meets Primary Endpoints: Results Released at Digestive Disease Week Conference|
Statistically Significant Results With 64% of Patients Showing > 50%
Reduction in ALT and AST Levels and 55% Achieving Normal Levels
Reductions Largely Sustained During 6 Months of Post-Treatment
Monitoring
NOVATO, Calif., May 3, 2010 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartr... |
| | | 04/07/10 | Raptor Pharmaceutical Announces Engagement of The Trout Group for Strategic Management of Investor Relations| NOVATO, Calif., Apr 7, 2010 (GlobeNewswire via COMTEX) --Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced the engagement of The Trout Group LLC, a leading New York-based investor relations and strategic advisory firm. The Trout Group will work with Raptor to facilitate the Company's exposure to the international capital markets and coordinate their communications with investors worldwide. With extensive institutional investor relationships in the United Stat... |
| | | 03/04/10 | Raptor Pharmaceutical Announces Publication of Data Supporting Potential Efficacy of WntTide(TM) in Treatment of Triple-Negative Breast Cancer| NOVATO, Calif., Mar 4, 2010 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced the publication of data on a proprietary, Mesd (Mesoderm development)-based peptide, also known as WntTide(TM), licensed by Raptor from Washington University in St. Louis, in the March 1 Early Addition of Proceedings of the National Academy of Sciences. The paper, titled, "LRP6 Overexpression Defines a Class of Breast Cancer Subtype and Is a Target for T... |
| | | 02/10/10 | Raptor Pharmaceutical Corp. to Present Cystinosis Research at Lysosomal Disease Network's 2010 WORLD Symposium| Forms European Subsidiary, Raptor Pharmaceuticals Europe BV
NOVATO, Calif., Feb 10, 2010 /PRNewswire via COMTEX/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced the presentation of cystinosis data at the Annual Lysosomal Disease Network WORLD Symposium 2010, being held February 10-12 in Miami, Florida. Biomarker data from a Phase IIb pilot study of Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") will be the subject of a pos... |
| | | 01/11/10 | Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis| Potential to Improve Treatment with Less Frequent Administration and Better TolerabilityNOVATO, Calif., Jan 11, 2010 /PRNewswire via COMTEX/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced the publication of results from a Phase 2a clinical trial of a prototype formulation of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). Ranjan Dohil, M.D., Professor of Pediatrics at the ... |
| |
|
